{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anaplastic+Lymphoma+Kinase+Genomic+Tumor+Aberrations",
    "query": {
      "condition": "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 2,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-21T23:29:12.251Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06362369",
      "title": "A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Advanced Solid Tumor",
        "Melanoma",
        "Metastasis",
        "Pleural Mesothelioma",
        "Renal Cell Carcinoma",
        "MSI-High",
        "Mismatch Repair Deficiency",
        "Colorectal Cancer",
        "Hepatocellular Carcinoma",
        "Hepatocellular Cancer",
        "Renal Cell Cancer",
        "Kidney Cancer",
        "Skin Cancer",
        "Non Small Cell Lung Cancer",
        "NSCLC",
        "Anaplastic Lymphoma Kinase Genomic Tumor Aberrations",
        "ALK Genomic Tumor Aberrations"
      ],
      "interventions": [
        {
          "name": "Alintegimod",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "7 Hills Pharma, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 126,
      "start_date": "2024-08-23",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-05-21T23:29:12.251Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06362369"
    },
    {
      "nct_id": "NCT05502237",
      "title": "Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Zimberelimab",
          "type": "DRUG"
        },
        {
          "name": "Domvanalimab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1021,
      "start_date": "2022-10-12",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-30",
      "last_synced_at": "2026-05-21T23:29:12.251Z",
      "location_count": 11,
      "location_summary": "Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Peoria",
          "state": "Illinois"
        },
        {
          "city": "Asheville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05502237"
    }
  ]
}